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AbstrAct
Objective To evaluate biomarkers of renal tubulointerstitial 
damage and function in type 1 diabetes with and without 
diabetic kidney disease.
Research design and methods Cross-sectional case-
control study of Diabetes Control and Complications Trial/
Epidemiology of Diabetes Interventions and Complications 
Study participants. Cases (N=43) had incident persistent 
estimated glomerular filtration rate (eGFR) <60 mL/
min/1.73 m2 with urinary albumin excretion >300 mg/24 
hour. Controls (N=43) had persistent eGFR >90 mL/
min/1.73 m2 and urinary albumin excretion <30 mg/24 
hour. Urinary and plasma biomarkers reflecting tubular 
injury, inflammation, fibrosis, secretion, and synthetic 
function were measured from stored specimens collected 
at the first study visit with reduced eGFR (for case 
participants) or the corresponding study year (for control 
participants).
Results Mean (SD) age was 51 (9) and 50 (8) years for 
case and control participants, and mean (SD) duration of 
diabetes was 30 (6) and 30 (5) years, respectively. Mean 
(SD) eGFR was 39 (14) and 103 (9) mL/min/1.73 m2 for 
case and control participants, and mean (SD) albumin 
excretion rate was 1978 (2914) and 10 (7) mg/day, 
respectively. Comparing cases with controls, significant 
differences were observed in each measured biomarker, 
including urine epidermal growth factor (mean 5.3 vs 
21.2 μg/g creatinine for case vs control participants, 
respectively), urine monocyte chemoattractant protein-1 
(596 vs 123 ng/g creatinine), urine galectin-3 (168 vs 52 
μg/g creatinine), plasma soluble tubular necrosis factor 
receptor-1 (3695 vs 1022 pg/mL), plasma galectin-3 (21.3 
vs 11.0 ng/mL), urinary clearances of hippurate (70 vs 167 
mL/min) and cinnamoylglycine (77 vs 317 mL/min), and 
plasma arginine-citrulline ratio (5.6 vs 7.7 μg/μg), each 
P<0.001.
Conclusions Marked abnormalities in biomarkers of 
kidney tubular injury, inflammation, fibrosis, secretion, 
and synthetic function accompany reduced eGFR and 
albuminuria in type 1 diabetes.
Trial registration number NCT00360893, NCT00360815.
InTROduCTIOn
Elevated urine albumin excretion (albu-
minuria) and reduced estimated glomerular 
filtration rate (eGFR) have long been viewed as 
the cardinal manifestations of diabetic kidney 
disease (DKD). These DKD manifestations 
are common in type 1 diabetes, can progress 
to end-stage renal disease, and are strongly 
associated with cardiovascular diseases and 
other adverse health outcomes.1 However, 
kidney functions beyond glomerular filtra-
tion and conservation of circulating proteins 
are also critical for maintaining homeostasis 
and health. In particular, renal tubular cells 
secrete small molecules and synthesize growth 
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significance of this study
What is already known about this subject?
Kidney disease is a common complication of 
types 1 and 2 diabetes. Diabetic kidney disease 
is usually assessed using estimated glomerular 
filtration rate (eGFR) and urine albumin excretion, 
which predominantly reflect damage to the kidney 
glomerulus.
What are the new findings?
Compared with people with type 1 diabetes and normal 
eGFR and urine albumin excretion, those with abnormal 
eGFR and urine albumin excretion had significant 
concomitant abnormalities in urine and plasma 
biomarkers that reflect damage and impaired function 
of the tubulointerstitital compartment of the kidney. 
The results suggest that tubular injury, inflammation, 
and fibrosis as well as impairments in kidney tubule 
secretion and synthesis of small molecules are 
prominent features of diabetic kidney disease.
How might these results change the focus of 
research or clinical practice?
This study suggests that diverse aspects of 
tubulointerstitial damage and function should be 
evaluated in future studies of diabetic kidney disease 
and provides new information on specific biomarkers 
that might be useful for this work. Ultimately, such 
studies may better define the pathophysiology of 
diabetic kidney disease, help develop new biomarkers 
to add to eGFR and urine albumin excretion in clinical 
care, and guide the development of new treatments for 
diabetic kidney disease.
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factors, hormones, and amino acids. Renal tubulointeres-
titial damage—not glomerular disease—is most strongly 
associated with progression of chronic kidney disease.2,3 
Further understanding of tubular damage, secretion, 
and synthesis may lead to better understanding of kidney 
injury in DKD, the relationship of kidney disease to other 
diabetes complications, and new therapeutic targets.
Research design and methods
We performed a cross-sectional case-control study nested 
within the Diabetes Control and Complications Trial/
Epidemiology of Diabetes Interventions and Complica-
tions (DCCT/EDIC) Study. The goal of the study was 
to identify candidate biomarkers of tubulointerstitial 
damage and function that are markedly abnormal in 
DKD in order to prioritize promising biomarkers for 
additional longitudinal studies.
We studied all participants with incident persistent eGFR 
<60 mL/min/1.73 m2 (on two consecutive study visits), 
urinary albumin excretion rate (AER) >300 mg/24 hour, 
and available biosamples (N=43). Controls (N=43) were 
randomly selected from DCCT/EDIC Study participants 
who maintained persistent eGFR >90 mL/min/1.73 m2 
and AER <30 mg/24 hour through the study visit on 
which the corresponding case participant developed inci-
dent eGFR <60 mL/min/1.73 m2. Control participants 
were matched to cases on duration of diabetes and DCCT 
cohort (primary vs secondary intervention).
Using stored urine and plasma specimens collected 
at the time of incident persistent eGFR <60 mL/
min/1.73 m2 (for cases) or at the same study year (for 
controls), we measured biomarkers reflecting tubular 
injury, inflammation, fibrosis, secretion, and synthetic 
function. These included urine epidermal growth factor 
(EGF), urine monocyte chemoattractant protein-1 
(MCP-1), plasma soluble tubular necrosis factor 
receptor-1 (sTNFR-1), urine and plasma galectin-3, the 
urinary clearances of hippurate and cinnamoylglycine, 
and plasma arginine-citrulline ratio. These biomarkers 
were chosen to represent diverse aspects of tubulointer-
stitial damage and function that are not captured well by 
eGFR and albuminuria, prioritizing those most likely to 
be feasible and useful based on published literature.4-9
Aliquots of plasma and urine were collected concur-
rently using standardized procedures and stored at 
<−70°C. For 66 participants (with samples collected 
prior to August 2012), urine aliquots were taken from 
4-hour collections. For 20 participants (with samples 
collected after August 2012), urine was taken from a 
random morning sample, based on a change in the 
EDIC Study protocol. Urine EGF, MCP-1, and sTNFR-1 
were measured using ELISA assays from R&D Systems. 
Urine and plasma galectin-3 were measured using 
ELISA assays from BGMedicine. Plasma and urine 
hippurate and cinnamoylglycine and plasma arginine 
and citrulline were measured by mass spectrometry.8,10
Urinary EGF, MCP-1, and sTNFR-1 were standard-
ized to urine creatinine concentration. The urinary 
clearances of hippurate and cinnamoylglycine were 
calculated within the subset of 66 participants with 
timed urine collections as urinary excretion rate 
divided by plasma concentration. Differences in 
biomarkers were tested using the paired T-test, based 
on the case-control design.
ResulTs
Mean age was 50.5 years and mean duration of diabetes 
was 30.1 years at the time of biospecimen collection. 
Case and control participants were similar with regard 
to characteristics used for matching (DCCT cohort 
and duration of diabetes) as well as age and gender 
(table 1). Mean (SD) eGFR was 39 (14) and 103 (9) mL/
min/1.73 m2 for case and control participants, and mean 
(SD) albumin excretion rate was 1978 (2914) and 10 (7) 
mg/day, respectively. Blood pressure and hemoglobin 
A1c (HbA1c) (particularly time-weighted HbA1c) were 
higher comparing case with control participants.
The distributions of each measured biomarker differed 
significantly comparing cases with controls (table 2). The 
urinary excretion of EGF was markedly lower in case 
versus control participants, while the urinary excretion 
of MCP-1 and galectin-3 were markedly higher. Plasma 
sTNFR-1 and galectin-3 concentrations were markedly 
higher in case versus control participants, while plasma 
arginine-citrulline ratio (a marker of tubular synthetic 
function) was lower. The urinary clearances of hippu-
rate and cinnamoylglycine were significantly lower in 
case versus control participants. For urinary biomarkers, 
results were similar among subsets of participants with 
timed compared with random urine samples.
dIsCussIOn
We observed marked abnormalities in biomarkers of 
tubulointerstitial damage and function comparing 
participants with type 1 diabetes, incident eGFR <60 mL/
min/1.73 m2, and AER >300 mg/24 hour to those without 
evidence of kidney disease. Differences in all eight candi-
date biomarkers were large and statistically significant, 
despite the modest sample size. The eight biomarkers 
represent diverse aspects of tubulointerstitial damage 
and function, including tubular injury, inflammation, 
fibrosis, secretion, and synthetic function. Our results 
demonstrate that DKD in type 1 diabetes is characterized 
by a broad range of abnormalities beyond reduced eGFR 
and albuminuria, and suggest that diverse facets of tubu-
lointerstitial damage and function should be evaluated in 
future studies.
Tubular damage, inflammation, and tubulointerstitial 
fibrosis are acknowledged mechanisms of DKD.2,6,11-13 
Therefore, the observation that markers of these 
processes are abnormal among patients with established 
DKD is not surprising. However, the large differences we 
observed reinforce the concept that tubulointerstitial 
damage is a critical feature of DKD. Moreover, markers 
of tubular injury, inflammation, fibrosis, secretion, and 
group.bmj.com on November 20, 2017 - Published by http://drc.bmj.com/Downloaded from 
3BMJ Open Diab Res Care 2017;5:e000461. doi:10.1136/bmjdrc-2017-000461
Table 1 Clinical characteristics of included DCCT/EDIC 









  Age (years) 50 (8) 51 (9)
  Duration of diabetes (years) 30 (5) 30 (6)
  Female gender 20 (47) 17 (40)
  DCCT intensive therapy 21 (49) 14 (33)
  DCCT primary cohort 22 (51) 22 (51)
Physical examination data
  Body mass index (kg/m2) 29.3 (5.2) 30.4 (6.0)
  Systolic BP (mmHg) 122 (14) 137 (21)
  Diastolic BP (mmHg) 75 (9) 76 (13)
Laboratory data
  eGFR (mL/min/1.73 m2) 103 (9) 39 (14)
  Albumin excretion rate (mg/day) 10 (7) 1978 (2914)
  Current HbA1c (%) 8.0 (1.0) 8.6 (1.7)
  DCCT/EDIC time-weighted 
HbA1c (%)
7.9 (0.6) 9.2 (1.1)
  EDIC time-weighted HbA1c (%) 7.9 (0.7) 9.1 (1.3)
  LDL cholesterol (mg/dL) 95 (29) 105 (39)
  HDL cholesterol (mg/dL) 60 (19) 52 (18)
  Triglycerides (mg/dL) 77 (35) 131 (73)
Cell contents are mean (SD) or N (%).
*Cases were defined by incident persistent eGFR <60 mL/
min/1.73 m2 with urinary AER >300 mg/24 hour; control subjects 
were randomly selected from the pool of DCCT/EDIC Study 
participants who maintained persistent eGFR >90 mL/min/1.73 
m2 and AER <30 mg/24 hour through the study visit on which the 
corresponding case participant developed incident eGFR <60 mL/
min/1.73 m2 and were additionally matched to cases on duration 
of diabetes and DCCT cohort.
AER, albumin excretion rate; BP, blood pressure; DCCT/EDIC, 
Diabetes Control and Complications Trial/Epidemiology of 
Diabetes Interventions and Complications; eGFR, estimated 
glomerular filtration rate; HDL, high-density lipoprotein; HbA1c, 
hemoglobin A1c; LDL. low-density lipoprotein.
Table 2 Biomarkers of tubulointerstitial damage and 
function among included DCCT/EDIC Study participants 
with and without kidney disease
Kidney disease status*







  EGF (μg/g) 21.2 (8.7) 5.3 (2.8) <0.0001
  MCP-1 (ng/g) 123 (100) 596 (860) <0.0001
  Galectin-3 (μg/g) 52 (35) 168 (145) <0.0001
Plasma biomarkers
  sTNFR-1 (pg/mL) 1022 (256) 3695 (1289) <0.0001
  Galectin-3 (ng/mL) 11.0 (5.3) 21.3 (6.6) <0.0001
  Arginine-citrulline 
ratio (μg/μg)
7.7 (2.8) 5.6 (1.9) 0.0004
Urinary clearance‡
  Hippurate (mL/min) 167 (72) 70 (79) <0.0001
  Cinnamoylglycine 
(mL/min)
317 (150) 77 (71) <0.0001
Cell contents are mean (SD).
*Cases were defined by incident persistent eGFR <60 mL/
min/1.73 m2 with urinary AER >300 mg/24 hour; control subjects 
were randomly selected from the pool of DCCT/EDIC Study 
participants who maintained persistent eGFR >90 mL/min/1.73 
m2 and AER <30 mg/24 hour through the study visit on which the 
corresponding case participant developed incident eGFR <60 mL/
min/1.73 m2 and were additionally matched to cases on duration 
of diabetes and DCCT cohort.
†Urinary biomarkers are expressed per gram of urine creatinine.
‡Urinary clearances are restricted to 66 participants with timed 
urine collections.
AER, albumin excretion rate; DCCT/EDIC, Diabetes Control and 
Complications Trial/Epidemiology of Diabetes Interventions and 
Complications; eGFR, estimated glomerular filtration rate; MCP-1, 
monocyte chemoattractant protein-1; sTNFR-1, plasma soluble 
tubular necrosis factor receptor-1.
Pathophysiology/Complications
synthetic function are not currently used in clinical care 
and may ultimately be useful adjuncts to eGFR and albu-
minuria. Our data identify promising biomarkers to 
evaluate in future longitudinal studies that evaluate this 
possibility.
Recently, in a diverse population of people with chronic 
kidney disease (most without diabetes), an agnostic anal-
ysis starting with transcriptomics of kidney biopsy tissue 
ultimately identified reduced urinary EGF as a strong 
predictor of progressive kidney disease.4 EGF is a growth 
factor produced by distal tubular cells that promotes 
tubular cell repair and regeneration. Membrane-bound 
TNFR-1 is involved in apoptosis, survival, and key aspects 
of inflammation and immune response. The soluble form, 
sTNFR-1, was previously associated with rapid kidney func-
tion decline and incident eGFR <60 mL/min/1.73 m2 in the 
Joslin study of type 1 diabetes.5 Urine MCP-1, a more specific 
marker of renal inflammation, was associated with eGFR 
loss in type 2 diabetes.6 Plasma concentration of GDF-15, a 
member of the TGF-β cytokine superfamily, correlated with 
GDF-15 expression in renal tubular cells and was associated 
with progression of kidney disease in populations with estab-
lished chronic kidney disease (with and without diabetes).7
Tubular functions, including secretion and synthetic 
function, have been less comprehensively studied in DKD. 
Many proposed uremic toxins are small organic molecules 
that circulate bound to plasma proteins, such as albumin, 
and are poorly filtered but actively secreted by proximal 
tubular cells. Hippurate and cinnamoylglycine are exam-
ples of such small molecules, which accumulate with kidney 
disease in a manner that is not necessarily proportional to 
reduction in GFR.8 Renal tubular cells also perform many 
synthetic functions, such as the production of arginine from 
citrulline.9 Additional renal synthetic functions include 
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production of hydroxylated vitamin D metabolites, gluco-
neogenesis, ammoniagenesis, and erythropoietin produc-
tion. Accumulation of uremic solutes and reduced synthesis 
of important nutrients and hormones may promote insulin 
resistance, atherosclerosis, and other pathologic processes 
contributing to adverse health outcomes of chronic kidney 
disease.8,14,15 Our results suggest that biomarkers of tubu-
lointerstitial damage and function previously examined in 
other populations and evaluated in this study may be useful 
in type 1 diabetes.
The main limitation of our study is the cross-sectional 
design, from which we cannot determine the sequence of 
change in renal biomarkers or the utility of tubulointersti-
tial biomarkers for predicting kidney disease progression or 
other complications. Compared with control participants, 
those with DKD had higher systolic blood pressure and 
a history of worse glycemic control, but we cannot deter-
mine the extent to which hyperglycemia and hypertension 
contributed to tubulointerstitial damage and impaired 
tubular function. We are unable to discern whether urine 
biomarkers arise from the tubulointerstitial compartment 
of the kidney or appear in the urine through filtration. 
In addition, our candidate biomarker approach neces-
sarily excludes some potentially important biomarkers. 
Study strengths include the simultaneous evaluation of 
biomarkers reflecting multiple aspects of tubulointersititial 
damage and function, the well-characterized cohort with 
robust control subjects, the use of novel and precise mass 
spectrometry assays for some analytes, and the strength of 
the observed associations.
COnClusIOn
In type 1 diabetes, marked abnormalities in biomarkers 
of kidney tubular injury, inflammation, fibrosis, secretion, 
and synthetic function accompany reduced eGFR and albu-
minuria. Longitudinal studies are needed to determine the 
time course over which these biomarkers of tubulointersti-
tial function change relative to eGFR and albuminuria and 
to determine whether these biomarkers are associated with 
DKD progression and complications. Biomarkers of tubu-
lointerstitial damage and function may be useful for the 
development of new therapies targeting DKD.
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